Insulet (PODD) vs West Pharmaceutical Services (WST)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
West Pharmaceutical Services (WST) has outperformed Insulet (PODD) over the past year, gaining 37.8% versus a loss of 57.1%. Over five years, WST leads with a -9.5% price change compared with -55.3% for PODD. West Pharmaceutical Services is the larger company by market cap ($25.49 billion vs $9.23 billion), about 2.8 times the size, while Insulet is growing revenue faster (+30.7% vs +6.3%).
On valuation, Insulet trades at a lower forward P/E (17.2x vs 36.2x for West Pharmaceutical Services). West Pharmaceutical Services pays a dividend yielding 0.24%, while Insulet does not currently pay one. West Pharmaceutical Services converts more of its revenue into profit, with a net margin of 16.1% versus 9.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PODD | WST |
|---|---|---|
| Share price | $133.12 | $362.13 |
| Market cap | $9.23B | $25.49B |
| 1-day change | -0.92% | -1.19% |
| YTD return | -52.73% | +33.20% |
| 1-year return | -57.14% | +37.79% |
| 5-year return | -55.29% | -9.47% |
| P/E ratio (TTM) | 24.93 | 46.37 |
| Forward P/E | 17.22 | 36.24 |
| EPS (TTM) | $5.34 | $7.81 |
| Dividend yield | 0.00% | 0.24% |
| Annual dividend | $0.00 | $0.87 |
| Revenue (latest FY) | $2.71B | $3.07B |
| Revenue growth (YoY) | +30.73% | +6.25% |
| Net income (latest FY) | $247.10M | $493.70M |
| Gross margin | 71.63% | 35.91% |
| Operating margin | 17.50% | 19.03% |
| Net margin | 9.12% | 16.06% |
| 52-week high | $354.88 | $386.00 |
| 52-week low | $126.40 | $223.83 |
| Distance from 52-week high | -62.49% | -6.18% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +28.43% | +13.50% |
| Average volume | 1.68M | 626.98K |
| Shares outstanding | 69.35M | 70.38M |
| Employees | 5,400 | 10,800 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- West Pharmaceutical Services is about 2.8 times larger than Insulet by market value ($25.49B vs $9.23B).
- WST has outperformed PODD by 94.9 percentage points over the past year.
- West Pharmaceutical Services trades at a higher earnings multiple (46.4x vs 24.9x trailing P/E).
- West Pharmaceutical Services is more profitable, keeping 16.1 cents of every revenue dollar as net income versus 9.1 cents for Insulet.
- Insulet grew revenue faster in its latest fiscal year (+30.73% vs +6.25%).
About Insulet
PODD stock →Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System.
Health Care · Medical/Dental Instruments · 5,400 employees
About West Pharmaceutical Services
WST stock →West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
Health Care · Medical/Dental Instruments · 10,800 employees
PODD vs WST FAQ
Which is bigger, Insulet or West Pharmaceutical Services?
West Pharmaceutical Services (WST) is larger, with a market capitalization of $25.49B compared with $9.23B for Insulet (PODD).
Which stock has performed better over the past year, PODD or WST?
WST returned +37.79% over the past 12 months, compared with -57.14% for PODD (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, PODD or WST?
PODD has the lower trailing P/E at 24.9, versus 46.4 for WST. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Insulet or West Pharmaceutical Services?
West Pharmaceutical Services pays a dividend yielding 0.24%, while Insulet does not currently pay a regular dividend.
Are Insulet and West Pharmaceutical Services in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.